Search

Displaying results 2091 - 2100 of 8573 in total
  1. Drug

    Liraglutide

    go.drugbank.com/drugs/DB06655
    ApprovedInvestigational

    [A6932] Liraglutide was granted FDA approval on January 25, 2010.[L6070] … Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.

  2. Drug

    Arotinolol

    go.drugbank.com/drugs/DB09204
    Investigational

    It has been studied for its potential to be an antihypertensive therapy.[T87] Artinolol is being developed by Sumitomo Pharmaceutical Co., Ltd. and it is currently under clinical trials.[L1168]

  3. Drug

    Trabectedin

    go.drugbank.com/drugs/DB05109
    ApprovedInvestigational

    On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas. … Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer.

  4. Drug

    Potassium perchlorate

    go.drugbank.com/drugs/DB09418
    ApprovedWithdrawn

    The use of potassium perchlorate as a component in sealing gaskets for food containers has been revoked by the FDA following the use being abandoned by the industry [L2365]. … Potassium perchlorate acts as a competitive inhibitor of iodine uptake by the thyroid gland and attenuates the production of the thyroid hormone.

    Products: Perchloracap Capsule 200mg
  5. Drug

    Potassium bicarbonate

    go.drugbank.com/drugs/DB11098
    ApprovedInvestigational

    [L1836] This FDA denomination classifies potassium bicarbonate as a GRAS ingredient.[L1837] … It is used in medicine as an antacid.[T141] It is registered in the FDA under the section of suitable, safe and effective ingredients for OTC antacids.

  6. Drug

    Technetium Tc-99m exametazime

    go.drugbank.com/drugs/DB09163
    Approved

    Exametazime, also known as hexamethylpropyleneamine oxime or HMPAO, acts as a chelating agent for the Tc-99m radioisotope.

  7. Drug

    Eflapegrastim

    go.drugbank.com/drugs/DB15001
    ApprovedInvestigational

    [L43135] In September 2022, eflapegrastim was approved by the US FDA as a prophylactic against infection, as manifested by febrile neutropenia, in patients receiving certain myelosuppressive anti-cancer … Febrile neutropenia (FN), defined as the co-occurrence of fever (temperature > 38 ◦C) and severe neutropenia (ANC < 500 cells/mm<sup>3</sup>), is a potential side effect of myelosuppressive chemotherapy

  8. Drug

    Mivacurium

    go.drugbank.com/drugs/DB01226
    ApprovedWithdrawn

    Mivacurium is a bisbenzylisoquinolinium based neuromuscular blocker or muscle relaxant. It binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscul...

  9. Drug

    Strontium ranelate

    go.drugbank.com/drugs/DB09267
    ApprovedWithdrawn

    Available for prescription use for a time in some parts of the world as Protelos (strontium ranelate) 2 g granules for oral suspension by Servier, it was ultimately discontinued in 2016-2017 owing to an … It is therefore promoted as a "dual action bone agent" (DABA) indicated for use in treatment of severe osteoporosis.

  10. Drug

    Coagulation Factor IX (Recombinant)

    go.drugbank.com/drugs/DB00100
    Approved

    It has a primary amino acid sequence that is identical to the Ala148 allelic form of human factor IX, and has structural and functional characteristics similar to those of endogenous factor IX. … IX complex), and is instead produced by a genetically engineered Chinese hamster ovary (CHO) cell line that secretes recombinant Factor IX into cell medium that is then processed and purified for use as